Convalescent Plasma Collection and Treatment in Pediatrics and Adults

NCT ID: NCT04376034

Last Updated: 2020-05-06

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: PHASE3
• Total Enrollment: 240 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2020-04-16
• Study Completion Date: 2021-03-30

Brief Summary

This is a prospective study, involving contacting potential plasma donors and the use of their plasma to help fight off infections of those suffering from COVID19 in accordance to collection guidelines for plasma and FDA IND requirement. This study will include up to 240 participants potentially receiving convalescent plasma and up to 1000 potential donors.

There are 3 basic arms to the study: mild, moderate and severe/critical severity. All 3 severity groups are eligible for enrollment, but mild severity will not be given plasma unless there is progression. Moderate severity will given up to 1 unit of plasma and severe/critical severity up to 2 units. There is no placebo group, however given the excepted issues of shortages of plasma, intention to treat will be used for analysis.

Detailed Description

Convalescent plasma (here on referred to as plasma) has been used in emergency life-threatening situations to treat infections for over 100 years. The plasma is donated by an individual that has recovered from the very same infection that another person is infected with. This plasma is enriched in the antibodies that recognize and helped the body's immune system fight off the infection. When transfused from donor to recipient those antibodies will aid the recipient in fighting off the infection. In recent history this has been used to fight Ebola. Recently, the Federal Food and Drug Agency (FDA) made possible expedited Investigational New Drug (IND) process for plasma use in the fight against COVID19 for emergency and lifesaving uses.

There are several other investigational drugs for treatment of COVID19 such as: Remdesivir, an antiviral. The off-label use of hydroxychloroquine, Lopinavir/ritonavir, or Tocilizumab have been authorized. Convalescent plasma mechanism of action helps to promote health by working with one's own immune system and will not interfere with the other proposed medications. It also will not weaken the immune system as the investigational and off label medications have the potential to do. Convalescent plasma is time honored and although investigational for each use against novel or rare infections, it is the basis for IgG infusions in the immunodeficient populations. Currently the use of IgG infusions such as Intravenous IgG (IVIG) is assumed to not have the right antibodies from donors in the general public. This is secondary to the novel nature of the COVID19 and the fact that the IVIG available today was collected 6 to 12 months ago from plasma donors; prior to the COVID19's outbreak discovery in China.

It is for that reason that IVIG is not recommended at this time and the FDA has made special fast-tracking announcements for plasma use for COVID19. Currently, plasma is the only treatment that has a previous history of success in these novel or rare viral outbreak situations. It has already been reported to have been associated with survival of 5 out of 5 participants in a pilot study in China

For the purpose of this study advanced respiratory support will include any measure of respiratory support above low flow nasal cannula oxygen (2 Liters/minute flow rate).

For the purpose of this study dyspnea will be defined as any shortness of breath that is not completely relieved with the use of low flow nasal canula oxygen set to 2 Liters/minute flow rate and/or requiring breathing treatments such as but not limited to: bronchodilators more than every 4 hours to relieve symptoms.

In the event that more than one recipient is identified and plasma is available in less than the total number of approved recipients, priority will be given to those approved by the FDA for the IND use of plasma for severe or critical condition. If there still exists a deficit of plasma, the priority will be given to those on advanced respiratory support with the most critical settings (if unclear then will be considered a tie); active pressor treatments; age <1 years of age with days of life, age adjusted for prematurity as a tie breaker; age >60 with years as a tie breaker; and lastly lottery pull with potential remaining recipients as the final tie breaker.

Conditions

COVID19; Coronavirus Infection; Coronavirus; Virus Diseases; RNA Virus Infections

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: SEQUENTIAL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Mild Severity

Eligible to enroll in study and will be monitored for progression. Will not initially receive plasma.

Group Type: OTHER

Standard of Care

Intervention Type: OTHER

Those that meet mild severity will be allowed to enroll in the study, but will not receive plasma unless there is progression of illness into the moderate/rapid progression or greater category.

Moderate Severity

Adult patients will be treated with 1 unit (200mL) of convalescent plasma

Pediatric patients will be treated with 10mg/kg up to 1 unit of convalescent plasma.

Group Type: ACTIVE_COMPARATOR

Convalescent Plasma 1 Unit

Intervention Type: BIOLOGICAL

Each adult recipient will receive 1 units of plasma, each unit will consist of about 200 to 250 mL.

Each pediatric recipient will receive 10mL/kg up to 1 unit of plasma.

Severe or Critical Severity

Adult patients will be treated with up to 2 units of convalescent plasma

Pediatric patients will be treated with 10mg/kg up to 2 units of convalescent plasma.

Group Type: ACTIVE_COMPARATOR

Convalescent Plasma 2 Units

Intervention Type: BIOLOGICAL

Those that meet severe or critical criteria will be given 2 units if available or 1 unit if 2 units are not available.

Those that are given 1 unit may receive the second unit (or the remainder of the maximum pediatric weight calculated amount of plasma up to 1 additional unit) if they progress to severe or critical condition or if already in severe or critical condition but only received 1 unit secondary to shortages.

Each pediatric recipient will receive 10mL/kg up to 2 units of plasma.

Interventions

Convalescent Plasma 1 Unit

Each adult recipient will receive 1 units of plasma, each unit will consist of about 200 to 250 mL.

Each pediatric recipient will receive 10mL/kg up to 1 unit of plasma.

Intervention Type: BIOLOGICAL

Convalescent Plasma 2 Units

Those that meet severe or critical criteria will be given 2 units if available or 1 unit if 2 units are not available.

Those that are given 1 unit may receive the second unit (or the remainder of the maximum pediatric weight calculated amount of plasma up to 1 additional unit) if they progress to severe or critical condition or if already in severe or critical condition but only received 1 unit secondary to shortages.

Each pediatric recipient will receive 10mL/kg up to 2 units of plasma.

Intervention Type: BIOLOGICAL

Standard of Care

Those that meet mild severity will be allowed to enroll in the study, but will not receive plasma unless there is progression of illness into the moderate/rapid progression or greater category.

Intervention Type: OTHER

Eligibility Criteria

Inclusion Criteria

• Plasma donation:

1. Prior diagnosis of COVID-19 documented by a laboratory test

1. Abbott RealTime SARS-CoV-2 real-time reverse transcription polymerase chain reaction (rRT-PCR) test on the Abbott m2000 System (Inpatient WVU testing)

2. Other testing methods and vendors using FDA approved detection methods of SARS-CoV-2 under the Emergency Use Authorization (EUA)

2. Complete resolution of symptoms at least 28 days prior to donation

3. Complete resolution of symptoms for at least 14 days with negative repeat COVID-19 testing approved by the FDA EUA

4. Female donors age 18+ that have never been pregnant or negative for HLA antibodies

5. Male donors age 18+

6. Negative results for COVID-19 either from one or more nasopharyngeal swab specimens or by a molecular diagnostic test from blood. A partial list of available tests can be accessed at https://www.fda.gov/medical-devices/emergency-situations-medical-devices/emergency-use-authorizations.

7. Defined SARS-CoV-2 neutralizing antibody titers, if testing can be conducted (e.g., of at least 1:1602, 1:360 up to 1:640 is preferred. In shortage case 1:80 is acceptable)

8. At least or greater than 50kg of weight

• Plasma Recipients:

1. Individuals of any age above 30 days of life, sex, or pregnancy status suffering from confirmed COVID19 and in rapid progression, severe or critical condition meeting the FDA IND guidelines.

2. Must have laboratory confirmed COVID19

3. Must have severe or immediately life-threatening COVID19

4. Must provide informed consent/assent

Exclusion Criteria

• Plasma donation:

1. Individuals that do not meet the requirement from the American Red Cross for plasma donation or equivalent

2. Individuals plasma that has not passed safety screening after procurement by the American Red Cross for plasma donation or equivalent

• Plasma Recipients

1. Individuals with COVID19 who are not in clinical concern for rapid progression, severe or critical condition

2. Individuals who are in critical condition that are not confirmed to have COVID19

3. Individuals with known Selective IgA Deficiency, that has not been found to be absent of anti-IgA antibodies

• Minimum Eligible Age: 31 Days
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

West Virginia University

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Brian Peppers, DO, PhD

Role: PRINCIPAL_INVESTIGATOR

WVU Medicine Children's

Locations

WVU Medicine

Morgantown, West Virginia, United States

Site Status: RECRUITING

Countries

United States

Central Contacts

Brian Peppers, DO, PhD

Role: CONTACT

brian.peppers@hsc.wvu.edu

304-594-2483

Lisa Giblin Sutton, PharmD

Role: CONTACT

giblinl@wvumedicine.org

304-293-0928

Other Identifiers

2004965705

Identifier Type: -

Identifier Source: org_study_id